Neuropathology of vigabatrin.
1. Neuropathological changes in experimental animals have been observed with vigabatrin treatment in mice, rats and dogs. 2. These changes have comprised intramyelinic oedema which is reversible on cessation of treatment. 3. In human studies so far, no intramyelinic oedema has been noted. It is not clear whether humans will show the neurotoxicity observed in animals; close monitoring of patients is indicated.
Graham
D
D
Integrated Toxicology Program, Duke University Medical Center, Durham, North Carolina 27710.
D000614:Aminocaproates / Q000633:toxicity*; D000818:Animals; D000927:Anticonvulsants / Q000633:toxicity*; D001921:Brain / Q000473:pathology; D004285:Dogs; D006801:Humans; D008252:Macaca fascicularis; D051379:Mice; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D051381:Rats; D011919:Rats, Inbred Strains; D013045:Species Specificity; D013997:Time Factors; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D020888:Vigabatrin